Top Australian (ASX) Growth Stocks

Top Australian (ASX) Growth Stocks

UPDATED Jun 29, 2022

What are the best Australian (ASX) Growth Stocks?

According to our Simply Wall St analysis these are the best Australian growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

55 companies meet this criteria in the Australian market

Amaero International Ltd engages in the research, development, manufacture, and sale of laser-based metal additive products in Australia.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: 3DA is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 98.7% below our estimate of its fair value

  • Earnings are forecast to grow 119.75% per year

Risks

  • Has less than 1 year of cash runway

  • Makes less than USD$1m in revenue (A$599K)

  • Does not have a meaningful market cap (A$40M)

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Etherstack plc, a wireless technology company, engages in licensing mission critical radio technologies to equipment manufacturers and network operators Australia and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: ESK's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 45% below our estimate of its fair value

  • Earnings are forecast to grow 46.57% per year

  • Became profitable this year

Risks

  • High level of non-cash earnings

  • Does not have a meaningful market cap (A$52M)

  • Volatile share price over the past 3 months

View all Risks and Rewards

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CUV's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 32.1% below our estimate of its fair value

  • Earnings are forecast to grow 29.38% per year

  • Earnings grew by 15.2% over the past year

Risks

  • Significant insider selling over the past 3 months

View all Risks and Rewards

Jervois Global Limited explores for and evaluates mineral properties in the United States, Brazil, Finland, Australia, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: JRV is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 87% below our estimate of its fair value

  • Earnings are forecast to grow 59.7% per year

Risks

  • Has less than 1 year of cash runway

  • Shareholders have been substantially diluted in the past year

View all Risks and Rewards

Polynovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: PNV's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 41.1% below our estimate of its fair value

  • Earnings are forecast to grow 72.36% per year

  • Became profitable this year

Risks

  • Large one-off items impacting financial results

View all Risks and Rewards

Nickel Industries Limited engages in nickel ore mining and nickel pig iron production operations in Singapore and Indonesia.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: NIC's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 61.3% below our estimate of its fair value

  • Earnings are forecast to grow 35.65% per year

  • Earnings have grown 56% per year over the past 5 years

Risks

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Tulla Resources Plc explores for, evaluates, and develops gold property in Australia.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: TUL's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 94.5% below our estimate of its fair value

  • Earnings are forecast to grow 81.79% per year

Risks

  • Makes less than USD$1m in revenue (A$249K)

  • Does not have a meaningful market cap (A$136M)

  • Large one-off items impacting financial results

View all Risks and Rewards

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CGS's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 62.2% below our estimate of its fair value

  • Earnings are forecast to grow 26.96% per year

  • Earnings grew by 2812.4% over the past year

Risks

  • Large one-off items impacting financial results

View all Risks and Rewards
Page 1 of 7